Brokerages Set Heron Therapeutics, Inc. (NASDAQ:HRTX) Target Price at $4.50

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have received a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $4.50.

Several equities research analysts recently commented on the stock. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Wednesday, October 8th. Finally, Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th.

Hedge Funds Weigh In On Heron Therapeutics

A number of large investors have recently made changes to their positions in HRTX. PKS Advisory Services LLC acquired a new stake in shares of Heron Therapeutics during the third quarter worth approximately $25,000. R Squared Ltd acquired a new position in Heron Therapeutics in the 2nd quarter valued at approximately $26,000. B. Riley Wealth Advisors Inc. purchased a new stake in Heron Therapeutics in the 2nd quarter worth approximately $26,000. Jones Financial Companies Lllp boosted its stake in shares of Heron Therapeutics by 5,541.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 23,661 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Heron Therapeutics during the 3rd quarter valued at $34,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

NASDAQ:HRTX opened at $1.28 on Wednesday. The stock has a fifty day simple moving average of $1.21 and a 200 day simple moving average of $1.48. The firm has a market capitalization of $234.70 million, a price-to-earnings ratio of -14.22 and a beta of 1.34. Heron Therapeutics has a 1-year low of $1.00 and a 1-year high of $2.68. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The business had revenue of $38.21 million during the quarter, compared to analysts’ expectations of $39.03 million. Sell-side analysts forecast that Heron Therapeutics will post -0.13 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.